Evidence map›Paper›PMID 40369319›Full record

ArticleEJNMMI reports2025

Comparison of inter- and intraobserver agreement between [

Hannes Leupe, Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Bliede Van den Broeck, Sander Jentjens, Annouschka Laenen, Elin Pauwels, Willem Lybaert, Eric Van Cutsem, Guy Bormans and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04552847 (Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04552847 phase2 / phase3completednot on this map

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

TypeinterventionalSponsorUniversitaire Ziekenhuizen KU LeuvenRan2020 to 2022Enrolled85ConditionsNeuroendocrine TumorsArmsAl18F-NOTA-octreotide, PET/CT, PET/MR
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hannes LeupeNuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-9080-2370
Niloefar Ahmadi BidakhvidiNuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Karolien GoffinNuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Bliede Van den BroeckNuclear Medicine, Department of Medical Imaging, Ghent University Hospital, Ghent, Belgium.
Sander JentjensNuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Annouschka LaenenLeuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Leuven, Belgium.
Elin PauwelsNuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Willem LybaertDepartment of Oncology, Antwerp University Hospital and NETwerk Antwerpen-Waasland CoE, Edegem, Belgium.
Eric Van CutsemDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Guy BormansRadiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium.
Timon VandammeDepartment of Oncology, Antwerp University Hospital and NETwerk Antwerpen-Waasland CoE, Edegem, Belgium.
Frederik CleerenRadiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium.
Jeroen DekervelDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Karen GeboesDigestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium.
Sigrid StroobantsNuclear Medicine, Antwerp University Hospital and Molecular Imaging and Radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Chris VerslypeDigestive Oncology, University Hospitals Leuven, Leuven, Belgium.
Christophe M DerooseNuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. christophe.deroose@uzleuven.be.ORCID http://orcid.org/0000-0002-6080-1577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study compares inter- and intraobserver agreement between [ MATERIALS AND

methodsThis is a secondary endpoint analysis from our multicenter trial (clin trial.gov identifier: NCT04552847) including 75 NEN patients who received both [

resultsResults demonstrated nearly perfect interobserver agreement for lesion characterization across all organs for both tracers (0.921 for [

conclusion[

Indexed as

[18F]AlF-NOTA-octreotide[68Ga]Ga-DOTATATEInterobserver agreementNeuroendocrine tumorSomatostatin receptor

Identifiers

PMID40369319
PMCPMC12078903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.